# A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Source: https://onco.cc/trials/nct05020015/  
OnCo record `nct05020015` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of TAK-007 in non-Hodgkin lymphoma, run by Takeda, active and no longer recruiting.

## Summary

A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL) is a phase 2 interventional study registered as NCT05020015 by Takeda, with 27 participants enrolled, started 2021-11-12 and due to reach its primary completion in 2024-06-16. Interventions recorded: TAK-007 and Chemotherapy Agents. Results have been posted on the registry.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05020015
- Phase: 2
- Setting: A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Sponsor: Takeda
- Enrolled: 27
- Outcomes: Number of Participants With Treatment Emergent Adverse Events (TEAEs): Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells 3 participants vs Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 6 participants vs Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 10 participants vs Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 7 participants; Overall Survival (OS): Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells 8.9 months vs Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells vs Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 8.4 months vs Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells; Progression-free Survival (PFS) Per Investigator: Dose Escalation: TAK-007 - 200×10^6 CD19-CAR+ Viable NK Cells 0.95 months vs Dose Escalation: TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 2.23 months vs Dose Expansion: Cohort 1 (LBCL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 2 months vs Dose Expansion: Cohort 2 (iNHL 3L+): TAK-007 - 800×10^6 CD19-CAR+ Viable NK Cells 5.62 months

## Sources

- ClinicalTrials.gov NCT05020015: https://clinicaltrials.gov/study/NCT05020015

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Takeda](https://onco.cc/companies/takeda/)

---
JSON: https://onco.cc/api/v1/entities/nct05020015.json